Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non‐invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low‐level viremia
Namyoung Paik, Dong Hyun Sinn, Ji Hae Lee, et al.
Liver International (2017) Vol. 38, Iss. 1, pp. 68-75
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2019) Vol. 25, Iss. 2, pp. 93-159
Open Access | Times Cited: 191
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 89
Should Treatment Indications for Chronic Hepatitis B Be Expanded?
Wen‐Juei Jeng, Anna S. Lok
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2006-2014
Open Access | Times Cited: 60
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma
Xinhe Zhang, Lin Guan, Haoyu Tian, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 42
Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B
Theodoros Voulgaris, Μargarita Papatheodoridi, Pietro Lampertico, et al.
Liver International (2019) Vol. 40, Iss. 3, pp. 484-495
Open Access | Times Cited: 53
Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination
Robert J. Wong, Harvey W. Kaufman, Justin K. Niles, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e791-e800
Closed Access | Times Cited: 24
Non-invasive tests for the prediction of primary hepatocellular carcinoma
Giovanni Marasco, Antonio Colecchia, Giovanni Faria Silva, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 24, pp. 3326-3343
Open Access | Times Cited: 34
Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B
Hannah Choi, Alexander Tonthat, Harry L.A. Janssen, et al.
Hepatology Communications (2021) Vol. 6, Iss. 5, pp. 935-949
Open Access | Times Cited: 29
Predictive Values of Biochemical Markers As Early Indicators for Severe COVID-19 Cases in Admission
Emin Gemcioğlu, Mehmet Davutoğlu, Ramis Çatalbaş, et al.
Future Virology (2021) Vol. 16, Iss. 5, pp. 353-367
Open Access | Times Cited: 28
Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data
Dong Hyun Sinn, Danbee Kang, Yewan Park, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation
Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 31
Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy
Byeong Geun Song, Dong Hyun Sinn, Sangah Chi, et al.
European Journal of Gastroenterology & Hepatology (2018) Vol. 30, Iss. 12, pp. 1447-1452
Closed Access | Times Cited: 21
Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
Hsin-Yeh Chen, Sheng‐Nan Lu, Chao‐Hung Hung, et al.
PLoS ONE (2020) Vol. 15, Iss. 11, pp. e0242113-e0242113
Open Access | Times Cited: 19
An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation
Jelena Djokić Kovač, Aleksandar Ivanović, Tamara Alempijević, et al.
Radiology and Oncology (2021) Vol. 55, Iss. 2, pp. 130-143
Open Access | Times Cited: 16
Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients
Kung–Hao Liang, Ming‐Wei Lai, Yang-Hsiang Lin, et al.
BMC Gastroenterology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
Jing Zhou, Fada Wang, Lanqing Li, et al.
Precision Clinical Medicine (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 11
Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease
Hideki Fujii, Makoto Fujii, Michihiro Iwaki, et al.
Hepatology Research (2023) Vol. 53, Iss. 5, pp. 391-400
Closed Access | Times Cited: 6
Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection
Xin Hao, Rong Fan, Hongmei Zeng, et al.
Journal of Clinical and Translational Hepatology (2023) Vol. 11, Iss. 7, pp. 1508-1519
Open Access | Times Cited: 6
The Impact of the Definitions of Clinical Phases on the Profiles of Grey-Zone Patients with Chronic Hepatitis B Virus Infection
Xiaoqian Xu, Hao Wang, Shan Shan, et al.
Viruses (2023) Vol. 15, Iss. 5, pp. 1212-1212
Open Access | Times Cited: 5
Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study
Chuanmeng Zhang, Jiayuan Wu, Juan Xu, et al.
Disease Markers (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 15
Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China
Yunfeng Zhu, Yifei Tan, Xi Xu, et al.
Medicine (2019) Vol. 98, Iss. 50, pp. e18319-e18319
Open Access | Times Cited: 13
TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease
Lin-Lin Feng, Ran-Yang Liu, Kun An, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?
Yen‐Chun Liu, Wen‐Juei Jeng
Current Hepatology Reports (2024) Vol. 23, Iss. 1, pp. 11-21
Closed Access | Times Cited: 1
A new combined predicting model using a non-invasive score for the assessment of liver fibrosis in patients presenting with chronic hepatitis B virus infection
Houda Ben Ayed, Makram Koubâa, S. Yaïch, et al.
Médecine et Maladies Infectieuses (2019) Vol. 49, Iss. 8, pp. 607-615
Closed Access | Times Cited: 11
Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective
Yao‐Chun Hsu, Cheng‐Hao Tseng, Yen‐Tsung Huang, et al.
Seminars in Liver Disease (2021) Vol. 41, Iss. 03, pp. 285-297
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top